Prosecution Insights
Last updated: November 20, 2026
Application No. 18/539,581

METHOD

Non-Final OA §102§103§112
Filed
Dec 14, 2023
Priority
Dec 14, 2022 — provisional 63/387,379
Examiner
DENT, ALANA HARRIS
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Babraham Institute
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
76%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
331 granted / 750 resolved
-15.9% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
54 currently pending
Career history
816
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
39.3%
-0.7% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 750 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant’s election without traverse of Group I (claims 1, 2, 4-6, 8-11, 13-17, 19 and 24) in the reply filed on September 25, 2026 is acknowledged. 3. Claims 1, 2, 4-6, 8-11, 13-17, 19-22, 24 and 25 are pending. Claims 20-22 and 25, drawn to non-elected inventions and non-elected species are withdrawn from examination. Claims 3, 7, 12 and 18 have been cancelled. Claims 2, 4, 6, 8, 11, 13, 14, 16, 17, 19, 20 and 22 have been amended. Claims 24 and 25 have been added. Claims 1, 2, 4-6, 8-11, 13-17, 19 and 24 are examined on the merits. Claim Objections 4. Claim 2 is objected to because of the following informalities: the negative and plus signs should be presented in the superscript font on line 2, CD8+ and CD4+. Correction is required. Specification 5. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. 6. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code, see page 1, lines 19, 20, 23, 25, 26 and 31-33; page 3, lines 34; page 6, lines 33 and 34; page 7, lines 5-8, 10, 17, 19; page 9, lines 9, 11 and 13; and page 10, lines 5 and 19. Applicant is request to review the entire document. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. 7. The disclosure is objected to because of the following informality: there are at at least ten nucleotides listed in Table 3 spanning pages 27 and 28. The MPEP 2421.01 states “[t]he sequence rules embrace all unbranched nucleotide sequences with ten or more bases and all unbranched, non-D amino acid sequences with four or more amino acids, provided that there are at least 10 “specifically defined” nucleotides or 4 “specifically defined” nucleotides or amino acids. The rules apply to all sequences in a given application, whether claimed or not.” All such sequences are relevant for the purposes of building a comprehensive database and properly assessing prior art. It is therefore essential that all sequences, whether only disclosed or also claimed, be included in the database.” Applicant is required to review the entire specification for similar errors. Correction is required. Nucleotide and/or Amino Acid Sequence Disclosures 8. REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES Items 1) and 2) provide general guidance related to requirements for sequence disclosures. 37 CFR 1.821(c) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of 37 CFR 1.821(a) must contain a "Sequence Listing," as a separate part of the disclosure, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of 37 CFR 1.821 - 1.825. This "Sequence Listing" part of the disclosure may be submitted: In accordance with 37 CFR 1.821(c)(1) via the USPTO patent electronic filing system (see Section I.1 of the Legal Framework for Patent Electronic System (https://www.uspto.gov/PatentLegalFramework), hereinafter "Legal Framework") as an ASCII text file, together with an incorporation-by-reference of the material in the ASCII text file in a separate paragraph of the specification as required by 37 CFR 1.823(b)(1) identifying: the name of the ASCII text file; ii) the date of creation; and iii) the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(1) on read-only optical disc(s) as permitted by 37 CFR 1.52(e)(1)(ii), labeled according to 37 CFR 1.52(e)(5), with an incorporation-by-reference of the material in the ASCII text file according to 37 CFR 1.52(e)(8) and 37 CFR 1.823(b)(1) in a separate paragraph of the specification identifying: the name of the ASCII text file; the date of creation; and the size of the ASCII text file in bytes; In accordance with 37 CFR 1.821(c)(2) via the USPTO patent electronic filing system as a PDF file (not recommended); or In accordance with 37 CFR 1.821(c)(3) on physical sheets of paper (not recommended). When a “Sequence Listing” has been submitted as a PDF file as in 1(c) above (37 CFR 1.821(c)(2)) or on physical sheets of paper as in 1(d) above (37 CFR 1.821(c)(3)), 37 CFR 1.821(e)(1) requires a computer readable form (CRF) of the “Sequence Listing” in accordance with the requirements of 37 CFR 1.824. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed via the USPTO patent electronic filing system as a PDF, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the PDF copy and the CRF copy (the ASCII text file copy) are identical. If the "Sequence Listing" required by 37 CFR 1.821(c) is filed on paper or read-only optical disc, then 37 CFR 1.821(e)(1)(ii) or 1.821(e)(2)(ii) requires submission of a statement that the "Sequence Listing" content of the paper or read-only optical disc copy and the CRF are identical. Claim Rejections - 35 USC § 112 9. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 10. Claims 6, 11, 13-15 and 24 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. a. Claim 6 recites the limitation "the effector functions" and “the killing functions” in lines 1-3. There is insufficient antecedent basis for these limitations in the claim. b. Claim 11 is indefinite in that it fails to point out what is included or excluded by the claim language. This claim is an omnibus type claim. In particular, claim 11 references Table 1. Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant's convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993) (citations omitted). c. Claim 14 cites “such as” in line 2 of the claim. This phrase is regarded as exemplary language. Hence, the claim is indefinite because the scope of the claim is not clear. The metes and bounds cannot be determined. d. Claim 24 recites the limitation "the enhanced effector functions" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 12. Claim(s) 1, 2, 4-6, 8-10, 16, 17, 19 and 24 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Salerno et al., (Trends in Immunology 41(3): 240-254, March 2020/ IDS reference #20 submitted February 26, 2024). Salerno discloses “MAP kinase signal-integrating kinases (Mnks) and p38 MAPK-activated protein-kinase-2 (MK2)… phosphorylate and inhibit the RNA-decay promoting activity of the [RNA-binding proteins] RBPs hnRNPA1, ZFP36L1, and ZFP36, respectively,”, thereby enhancing cytotoxic T lymphocyte (CTL) activation and/or proliferation, see page 249, 2nd paragraph (para.). These RBPs are post-transcriptional regulators of gene expression. “[R]BPs alter their function to govern CD8+ T cell activation and differentiation.”, see page 241, sentences before “RNA-Binding…” segment. Given Salerno teaches the instant method recited in claim 1, it further reads on the wherein, CTL activation is enhanced independent of enhancing proliferation; effector functions of the CTLs are enhanced, thereby releasing granzyme B, perforin, TNFa, IFNg and/or IL-2; the gene encoding the post-transcriptional regulator(s) of gene expression is disrupted; one or RBPs regulate the stability and/or translation efficiency of an mRNA transcript; and one or more RBPs reduce or inhibit the stability and/or translation efficiency of the mRNA transcript, see page 245, 1st and 2nd paragraphs (paras.); and page 247, 2nd para. Absent evidence to the contrary, the method is performed in vitro. Claim Rejections - 35 USC § 103 13. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 14. Claim(s) 1, 2, 4-6, 8-11, 13, 16, 17, 19 and 24 is/are rejected under 35 U.S.C. 103 as being unpatentable over Salerno et al., (Trends in Immunology 41(3): 240-254, March 2020/ IDS reference #20 submitted February 26, 2024), and further in view of Yeo et al., US 2022/0127611 A1 (effectively filed October 27, 2021) and Alnaefaie et al., (Frontier in Bioengineering and Biotechnology 10(797440): 1-32, published 22 June 2022). Salerno teaches “MAP kinase signal-integrating kinases (Mnks) and p38 MAPK-activated protein-kinase-2 (MK2)… phosphorylate and inhibit the RNA-decay promoting activity of the [RNA-binding proteins] RBPs hnRNPA1, ZFP36L1, and ZFP36, respectively,”, thereby enhancing cytotoxic T lymphocyte (CTL) activation and/or proliferation, see page 249, 2nd paragraph (para.). These RBPs are post-transcriptional regulators of gene expression. “[R]BPs alter their function to govern CD8+ T cell activation and differentiation.”, see page 241, sentences before “RNA-Binding…” segment. Given Salerno teaches the instant method recited in claim 1, it further reads on the wherein, CTL activation is enhanced independent of enhancing proliferation; effector functions of the CTLs are enhanced, thereby releasing granzyme B, perforin, TNFa, IFNg and/or IL-2; the gene encoding the post-transcriptional regulator(s) of gene expression is disrupted; one or RBPs regulate the stability and/or translation efficiency of an mRNA transcript; and one or more RBPs reduce or inhibit the stability and/or translation efficiency of the mRNA transcript, see page 245, 1st and 2nd paragraphs (paras.); and page 247, 2nd para. Absent evidence to the contrary, the method is performed in vitro. Salerno does not teach the method, wherein the one or more post-transcriptional regulators of gene expression is any one or more of those listed in Table 1 and/or is one or more components of the Carbon Catabolite Repression 4-Negative On TAT-less (CCR4-NOT) complex. Nor, does Salerno teach the method, wherein the CTL is an engineered T cell, chimeric antigen receptor (CAR) T cell able to recognize and react to a tumour antigen. However, Yeo teaches RBPs, AGO2, ASCC3, CNBP, CPSF6, DDX28, DHX30, HNRNP2AB1, HNRNPM, HNRNPP2, MBNL1, PTBP1, ZFP36L2, ZRANB2, LARP4, NUFIP2, RBM12, RBM26, RBM38, SCAF8, SFRS10, SREK1, SUGP1, ZC3HAV1, ZRANB2, as well as components of the CCR4-NOT, CNOT4, CNOT6L, DDX6, HNRNPF, see page 1, sections 0003 and 0007; page 6, sections 0098 and 0099; and Table 1 spanning pages 9-12, 14-16, 19, 20, 22-24 and 26. Furthermore, Alnefaie teaches CAR T cells, genetically engineered T cells able to facilitate cancer treatment, see entire document. It would have been obvious for a person of ordinary skill in the art, as of the effective filing date of the claimed invention, to include the additional RBPs taught by Yeo in order to assess their impact on CTL activation and/or proliferation as taught in Salerno, as well as test their impact on CAR T cells. A person of ordinary skill would have been motivated to do so because Salerno evidences RBPs are crucial components in “…post-transcriptional control during CD8+ T cell homeostasis and activation.”, see abstract on page 240; and entire document. Thus, in view of the teachings of Salerno, Yeo and Alnefaie, there would have been a reasonable expectation that additional RBPs would yield additional information regarding their impact on mammalian T cell effector functions and engineered T cells, as well as how their inhibition and/or reduction of activity impacts “…the magnitude and timing of cytokine production in CD8+ T cells” and “…govern CD8+T cell activation and differentiation”, see pages 240, 241; and entire document. Conclusion 15. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ALANA HARRIS DENT whose telephone number is (571)272-0831. The Examiner works a flexible schedule, however she can generally be reached on 8AM-8PM, Monday through Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Julie Wu can be reached on 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ALANA HARRIS DENT Primary Examiner Art Unit 1643 20 October 2026 /Alana Harris Dent/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Dec 14, 2023
Application Filed
Nov 04, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782354
Cancer Progression Risk Assessment by Microvascular Phenotype
5y 3m to grant Granted Nov 03, 2026
Patent 12780944
ANTI-MASP2 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12767989
A METHOD OF TREATING, DIAGNOSING AND MONITORING MELANOMA UTILISING MICRORNAS
5y 3m to grant Granted Oct 20, 2026
Patent 12758572
TREATMENTS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
3y 0m to grant Granted Oct 13, 2026
Patent 12716896
ANTIBODY ASSAY
7y 3m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
76%
With Interview (+32.2%)
3y 8m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 750 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month